That FDA PR was issued back in November - it is no

That FDA PR was issued back in November - it is nothing new. It was for for casirivimab and imdevimab: “to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19. “